Research programme: beta-secretase inhibitors - Johnson & Johnson Innovative Medicine/Shionogi
Alternative Names: BACE inhibitors - Johnson & Johnson Innovative Medicine/ShionogiLatest Information Update: 10 Oct 2023
Price :
$50 *
At a glance
- Originator Shionogi
- Developer Johnson & Johnson Innovative Medicine; Shionogi
- Class Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)